Skip to content

Analysis of the timing of endoscopic treatment for esophagogastric variceal bleeding in cirrhosis: a prospective randomized controlled study

Analysis of the timing of endoscopic treatment for esophagogastric variceal bleeding in cirrhosis: a prospective randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068528
Enrollment
Unknown
Registered
2023-02-22
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophagogastric variceal bleeding in cirrhosis

Interventions

Group 1:endoscopy duration 12 h

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with liver cirrhosis have obvious signs of upper gastrointestinal bleeding (hematemesis, melena and/or blood in stool, blood or coffee-colored liquid drawn out by nasogastric tube), with or without hypotension (systolic blood pressure in supine position = 100 times/ minute); 2. Age > 18 years old; 3. Patients or their legal representatives voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. History of organ dysfunction: heart failure, renal failure, etc.; 2. People with mental illness who cannot cooperate with endoscopy; 3. Patients who are in hypotensive shock state or whose condition has not stabilized after initial resuscitation and need emergency intervention; 4. Patients with other malignant tumors other than liver malignant tumors; 5. Upper gastrointestinal bleeding caused by other reasons than cirrhotic variceal bleeding, such as peptic ulcer, gastric tumor, etc.; 6. Pregnant women; 7. The researcher believes that there are other reasons that are not suitable for participating in this study.

Design outcomes

Primary

MeasureTime frame
rebleeding rate at 6 weeks;

Secondary

MeasureTime frame
success rate of emergency hemostasis;6 overall cause of death;incidence of rescue treatment;total number of transfused red blood cell units;the length of time;hospital costs;

Countries

China

Contacts

Public ContactXiaodong Zhou

The First Affiliated Hospital of Nanchang University

zhouxdncu@163.com+86 137 6703 8587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026